NEW YORK – NeoGenomics on Tuesday reported a 20 percent year-over-year increase in its third quarter revenues, primarily due to higher testing volume.
For the three months ended Sept. 30, total revenues reached $125.4 million, up from $104.7 million in Q3 2019, but short of the consensus analysts' estimate of $126.2 million.